After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that MacroGenics to Participate in Upcoming Investor Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $12.11 and fluctuated between $12.47 as its day high and $11.93 as its day low. The current market capitalization of Macrogenics Inc is $751.18M. A total of 1.09 million shares were traded on the day, compared to an average of 725.07K shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, MGNX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 6 BUYs and 3 SELLs from insiders. Insiders purchased 883,125 shares during that period but sold 12,369.
In the most recent transaction, Bonvini Ezio sold 13,316 shares of MGNX for 12.00 per share on Jan 19. After the transaction, the Sr VP, Research & CSO now owns 87,984 company shares. In a previous transaction on Dec 20, Bonvini Ezio sold 18,880 shares at 10.08 per share. MGNX shares that Sr VP, Research & CSO owns now total 101,300.
Among the insiders who bought shares, BIOTECH TARGET N V acquired of 150,000 shares on Oct 02 at a per-share price of $4.46. This resulted in the 10% Owner holding 9,929,963 shares of MGNX after the transaction. In another insider transaction, BIOTECH TARGET N V bought 200,000 shares at $5.26 per share on Sep 07. Company shares held by the 10% Owner now total 9,779,963.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for MGNX in the last 3 months, the mean price target is $13.67 with high estimates of $20.00 and low estimates of $10.00. In terms of 52-week highs and lows, MGNX has a high of $12.10 and a low of $4.29.
As of this writing, MGNX has an earnings estimate of -$0.14 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of $0.38 per share and a lower estimate of -$0.37. The company reported an EPS of $0.92 in the last quarter, which was 276.90% higher than expectations of -$0.52.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MGNX’s latest balance sheet shows that the firm has $243.62M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $74.58M in liabilities at the time. Its Book Value Per Share was $3.13, while its Total Shareholder’s Equity was $239.62M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MGNX is Buy with a score of 4.64.
